---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-079816"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2025-08-18T23:59:59+00:00"
generated_at: "2026-05-17T11:52:26.736539+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# iBio updates corporate presentation; posts preliminary cash of $8.8M as of June 30, 2025

## Summary
- Preliminary cash of $8.8M as of June 30, 2025; audited FY2025 results expected later this quarter.
- IBIO-610 (Activin E antibody) showed 8.9% body weight loss, 26% fat reduction, no lean mass loss in DIO mice.
- IBIO-610 + semaglutide achieved 35.3% weight loss vs 27.8% alone; prevented weight regain after GLP-1 cessation.
- IBIO-600 (anti-myostatin) half-life 40-52 days in NHPs; human estimate 57-147 days; CMC and GLP tox ongoing.
- Partnered with AstralBio to develop amylin receptor agonist antibodies for obesity treatment.

## SEC filing metadata
- accession: 0001104659-25-079816
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2025-08-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000110465925079816/0001104659-25-079816-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000110465925079816/tm2523706d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-079816
- JSON: https://secwatch.observer/filing/0001104659-25-079816.json
- Plain text: https://secwatch.observer/filing/0001104659-25-079816.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.